Clinical Trial Search

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Overall Survival — 15.7; 9.0 months — p=0.0024

Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants

Primary: Number of Participants With Residual Disease — 24 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: One Year Survival Rate — 0.502 proportion of patients

Primary: Overall Survival — 4.2; 8.3 months — p=0.36

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale

Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants

Primary: Time-to-Treatment Failure (Intent-To-Treat Analysis) — 4.9; 2.7; 2.2; 3.7 months

Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants

Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78

Primary: Disease Control Rate — 25 percentage of participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants

Primary: Tumor Response — 5; 3 Participants

Primary: Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical…

Primary: Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone — 16.20; 14.16 Months — p=0.039

Primary: Recurrence Free Survival — 15.6 months

Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)

Primary: Percent of Ki-67 Positive Cells — .4023; .5872; .3732; .5035 percentage of stained tumor cell nuclei

Primary: Overall Survival — 226; 209 days — p=0.6647

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants

Primary: Part 1: Maximum Tolerated Dose (MTD) of Capecitabine — 900 mg/m^2 BID

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants